2-[(2-methoxy-phenoxy)-(2-methoxy-phenyl)-methyl]-morpholine | 71621-38-0

• 分子结构分类: 有机化合物 - 苯类化合物 - 苯酚醚
• 英文名称: 2-[(2-methoxy-phenoxy)-(2-methoxy-phenyl)-methyl]-morpholine
• 英文别名: 2-[α-(2-methoxy-phenoxy)-2-methoxy-benzyl]-morpholine；2-[alpha-(2-methoxy-phenoxy)-2-methoxy-benzyl]-morpholine；2-(o-Methoxy-alpha-(o-methoxyphenoxy)benzyl)morpholine；2-[(2-methoxyphenoxy)-(2-methoxyphenyl)methyl]morpholine
• CAS: 71621-38-0
• 化学式: C₁₉H₂₃NO₄
• 分子量: 329.396
• InChiKey: DPUGCYZBXXHQEL-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  2.6
• 重原子数：
  24
• 可旋转键数：
  6
• 环数：
  3.0
• sp3杂化的碳原子比例：
  0.37
• 拓扑面积：
  49
• 氢给体数：
  1
• 氢受体数：
  5

反应信息

• 作为产物：
  描述：

  红铝 以33%的产率得到
  参考文献：
  名称：

  MELLONI, P.;CARNIEL, G.;DELLA, TORRE, A.;BONSIGNOR, A.;BUONAMICI, M.;POZZ+, EUR. J. MED. CHEM., 1984, 19, N 3, 235-242

  摘要：

  DOI：

文献信息

• Method for treatment of depression and anxiety disorders by combination therapy
  申请人：Arneric P. Stephen

  公开号：US20050059654A1

  公开（公告）日：2005-03-17

  A method is provided of treating depression in mammals, including a human, as well as depression and a concomitant disease, disorder or condition exemplified by, but not limited to, anxiety, sleep disorder and post-traumatic stress disorder. The method comprises administering to the mammal in effective amount a combination of active ingredients comprising a) an alpha-2delta (A2D) ligand or a prodrug thereof, or a pharmaceutically acceptable salt of said A2D ligand or said prodrug and, active agents selected from; (b) a selective serotonin re-uptake inhibitor (SSRI) or a prodrug thereof or a pharmaceutically acceptable salt of said SSRI or said prodrug, (c) a selective noradrenaline re-uptake inhibitor (SNRI) or a prodrug thereof or a pharmaceutically acceptable salt of said SNRI or said prodrug and mixtures of (b) and (c). A pharmaceutical composition comprising a therapeutically effective amount (a) an A2D ligand or a prodrug thereof, or a pharmaceutically acceptable salt of said A2D ligand or said prodrug and active agents selected from; (b) an SSRI or a prodrug thereof or a pharmaceutically acceptable salt of said SSRI or said prodrug, (c) an SNRI or a prodrug thereof or a pharmaceutically acceptable salt of said SNRI or said prodrug and mixtures of (b) and (c) is also provided. Preferred active ingredients for the treatment and the pharmaceutical composition include pregabalin, gabapentin, sertraline and reboxetine.

  本发明提供了一种治疗哺乳动物（包括人类）抑郁症的方法，以及抑郁症和伴随疾病、障碍或状况的方法，例如但不限于焦虑症、睡眠障碍和创伤后应激障碍。该方法包括向哺乳动物施用有效量的活性成分组合，其中包括 a) α-2δ（A2D）配体或其原药，或所述 A2D 配体或所述原药的药学上可接受的盐，以及选自以下各项的活性剂；(b) 选择性血清素再摄取抑制剂（SSRI）或其原药或所述 SSRI 或所述原药的药学上可接受的盐， (c) 选择性去甲肾上腺素再摄取抑制剂（SNRI）或其原药或所述 SNRI 或所述原药的药学上可接受的盐，以及 (b) 和 (c) 的混合物。还提供了一种药物组合物，该组合物包含治疗有效量的(a) A2D 配体或其原药，或所述 A2D 配体或所述原药的药学上可接受的盐和选自以下的活性剂；(b) SSRI 或其原药或所述 SSRI 或所述原药的药学上可接受的盐；(c) SNRI 或其原药或所述 SNRI 或所述原药的药学上可接受的盐以及(b)和(c)的混合物。用于治疗和药物组合物的优选活性成分包括普瑞巴林、加巴喷丁、舍曲林和雷贝西汀。
• Melloni; Carniel; Della Torre, European Journal of Medicinal Chemistry, 1984, vol. 19, # 3, p. 235 - 242
  作者：Melloni、Carniel、Della Torre、et al.

  DOI：——

  日期：——
• COMBINATION COMPRISING AN ALPHA-2-DELTA LIGAND AND AN SSRI AND/OR SNRI FOR TREATMENT OF DEPRESSION AND ANXIETY DISORDERS
  申请人：Warner-Lambert Company LLC

  公开号：EP1675582A1

  公开（公告）日：2006-07-05
• Soft tissue implants and drug combination compositions, and use thereof
  申请人：Hunter L. William

  公开号：US20070196421A1

  公开（公告）日：2007-08-23

  Soft tissue implants (e.g., breast, pectoral, chin, facial, lip, and nasal implants) are used in combination with an anti-scarring drug combination in order to inhibit scarring that may otherwise occur when the implant is placed within an animal.
• Anti-scarring drug combinations and use thereof
  申请人：Hunter L. William

  公开号：US20070208134A1

  公开（公告）日：2007-09-06

  The present invention provides devices or implants that comprise anti-scarring drug combinations, methods or making such devices or implants, and methods of inhibiting fibrosis between the devices or implants and tissue surrounding the devices or implants. The present invention also provides compositions that comprise anti-fibrotic drug combinations, and their uses in various medical applications including the prevention of surgical adhesions, treatment of inflammatory arthritis, treatment of scars and keloids, the treatment of vascular disease, and the prevention of cartilage loss.